Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Unite for Parkinson's dinner in Rome

Global update

#UniteForParkinsons around the world

The 2018 #UniteForParkinsons campaign reaches 8 million

READ MORE
Work and Parkinson's

Episodes

Podcast: What’s it like managing your working life with Parkinson’s?

Our guests reflect on work life with Parkinson's

READ MORE
Businessman Relaxing On Train Listening To Music

Resources & Tools

The Parkinson’s Foundation releases series of free Parkinson’s podcasts

Enjoy these free Parkinson’s podcasts

READ MORE